# Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

> **NCT06489548** · PHASE2 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 16 (estimated)

## Conditions studied

- Dementia
- Alzheimers Disease
- Mild Cognitive Impairment Due to Alzheimer's Disease

## Interventions

- **DRUG:** Foralumab TZLS-401 50 µg
- **DRUG:** Foralumab TZLS-401 100 µg

## Key facts

- **NCT ID:** NCT06489548
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-16
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06489548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06489548, "Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06489548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*